Klebsiella pneumoniae strains producing extended-spectrum b-lactamases (ESBL) exhibit resistance to antibiotic classes. The production of ESBLs (TEM-1, TEM-2, SHV-1, OXA-1) results in resistance to ampicillin, ticarcillin, piperacillin and cephalosporins. High levels of b-lactamases leads to development of resistance to b-lactamase inhibitors. The present study deals with characterizing antimicrobial resistance pattern among septicemia causing K. pneumoniae and the prevalence of inhibitor resistant OXA-1 b-lactamase genes among them. Of 151 study isolates, 59 were resistant to piperacillin/tazobactam and these isolates were further selected for blaOXA-1 screening. Amplification of b-lactamases genes by conventional PCR showed the presence of blaOXA-1 genes among 12 K. pneumoniae (20.3%) isolates. OXA-1 blactamase producing strains were found to be resistant to piperacillin/tazobactam(100%), levofloxacin (91.6%), amikacin (75%), cefoxitin (50%), ertapenem (25%), imipenem (16.6%) and meropenem (16.6%); all were susceptible to tigecycline. 3D models of OXA-1 b-lactamase were generated and docking was performed with various b-lactam antibiotics. Molecular docking (MD) revealed the molecular basis of drug sensitivity. MD simulation results clearly confirmed the notable loss in stability for tigecycline-blaOXA-1 complex. Findings of the present study will provide useful insights for understanding the mechanism of resistance and help with strategies for the development of new antibiotics. The conventional PCR assay designed in this study can be routinely used in clinical microbiology laboratories to determine the blaOXA-1genes. 
Introduction
Klebsiella pneumoniae is a Gram negative, non motile, encapsulated, facultative anaerobic, lactose fermenting, rod shaped bacterium. The range of clinical diseases caused by this includes pneumonia, thrombophlebitis, urinary tract infection (UTI), bacteremia and septicemia. Indiscriminate antibiotic use is a major factor that often result in multi drug resistant strains. The production of broad-spectrum b-lactamases (TEM-1, TEM-2, SHV-1, OXA-1) results in resistance to ampicillin, ticarcillin, piperacillin and cephalosporins. Three enzymatic mechanisms have been described for resistance to inhibitor penicillin combinations: i.) production of class C chromosomal b-lactamase [1] , ii.) hyperproduction of plasmid-mediated TEM-1and TEM-2 [2] , and iii.) production of OXA-1 b-lactamase [3] . The blaOXA-1 gene has been found in plasmid and integron locations in a large variety of Gram-negative organisms. The blaOXA-1 gene has frequently been found to be associated with genes encoding extended-spectrum b-lactamases (ESBLs). OXA-1 b-lactamase, like most OXAs, hydrolyzes amino and ureidopenicillins (piperacillin) significantly and hydrolyzes narrow-spectrum cephalosporins weakly. In addition, blaOXA-1 hydrolyzes broad-spectrum cephalosporins, conferring reduced susceptibility to cefepime and cefpirome. Recent studies have reported very frequent association of blaOXA-1 with the worldwide-spread CTX-M-15 ESBL determinant found among human E.coli isolates from diverse geographical origins. This association of blaOXA-1 with blaCTX-M genes makes isolates resistant to b-lactam-b-lactamase inhibitor combinations [4] . Studies conducted by our group over the last 5 years has shown increasing ESBL proportion [5] with multiple co carriage of ESBL, Amp C and NDM enzymes. There are not many Indian studies on blaOXA-1 gene, through there are a few studies on blaOXA-1 gene along with association of ESBL (TEM, SHV and CTX-M) genes. Therefore, we attempted to evaluate the prevalence of blaOXA-1 gene in our settings and determine an insilico approach that explores the mechanism of resistance by OXA-1 b-lactamases.
Materials and Methods
In this prospective laboratory based surveillance study, Gramnegative strains K. pneumoniae (n = 151) determined to be clinically significant from blood stream infections were collected at from five Indian tertiary care centers namely-All The antimicrobial susceptibility test were performed to determine the resistance profile of antimicrobial agent against: ampicillin (10 mg), cefotaxime (30 mg), ceftazidime (30 mg), cefoxitin (30 mg), cefepime(30 mg), cefpirome(30 mg), piperacillin/tazobactam(100 mg/10 mg), amikacin(30 mg), levofloxacin(30 mg), imipenem(10 mg), meropenem(10 mg), ertapenem(10 mg) and tigecycline (10 mg) were determined by the Kirby Bauer disc diffusion method. Piperacillin/tazobactam resistant isolates were used for further screening. Results were interpreted as per the Clinical and Laboratory Standards Institute (CLSI) 2011 guidelines [6] .
MIC was performed to determine the resistance profile to the following antimicrobials: ampicillin, cefotaxime, ceftazidime, cefoxitin, cefepime, cefpirome, piperacillin/tazobactam, amikacin, levofloxacin, imipenem, meropenem, ertapenem and tigecycline. E-test (Biomerieux, Craponne, France) method was used and results interpreted as per manufacturers guidelines.
Molecular Methods
A single colony of each organism was inoculated from a blood agar plate into 5 ml of Nutrient broth (BD, MD, USA) and incubated for 16-18 h at 37uC. Cells from 1.5 ml of the overnight culture were harvested by centrifugation at 8000 rpm for 5 min. After the supernatant was decanted, the pellet resuspended in 500 ml of distilled water. Then cells was lysed by heating at 95uC for 10 min, and cellular debris was removed by centrifugation at 8000 rpm for 5 min. Supernatant, (2 ml), was used as the DNA template source for amplification.
The supernatant (2 ml) was used as the source of DNA template for amplification. PCR was performed with a final volume of 25 ml in 0.2-ml thin-walled tubes. The primer sequences were as follows : blaOXA-1 forward, 59 TTTTCTGTTGTTTGGGTTTT 39; blaOXA1 reverse, 59 TTTCTTGGCTTTTATGCTTG 39 [7] . Each reaction contained 20 mM Tris-HCl (pH 8.4); 50 mM KCl; 0.2 mM each deoxynucleotide triphosphate; 1.5 mM MgCl2; primers OXA-1 F, OXA-1 R, and 1.25 U of Taq DNA polymerase (Fermentas). The PCR program consisted of an initial denaturation step at 95uC for 2 min, followed by 30 cycles of DNA denaturation at 94uC for 45 s, primer annealing at 55uC for 30 s and extension 72uC, 1 min [7] . After the last cycle, a final extension step at 72uC for 5 min was added. Fifteen-microliter aliquots of PCR product were analyzed by gel electrophoresis with 2% agarose (USB Corporation, Cleveland, USA). Gels were stained with ethidium bromide at 1.5 mg/ml and visualized by UV transillumination. A 100-bp DNA ladder (Fermentas International Inc. Burlington, Canada) was used. Clinical strain 3MBO9 (blaOXA-1, 427 bp) was used as positive control, negative control was PCR mix with water in place of template DNA.
The statistical analysis was conducted using SPSS package version 16.0 (IBM, New York, USA). Pearson product moment correlation was used to test for the association between variables (ESBL production and antibiotic resistance).The statistical analysis was run at 95% confidence limit and p-values,0.006 were considered as significant.
Bioinformatics
The Target sequence of blaOXA-1 was retrieved from UniProt [8] , accession number: R4WC18 and modelled using modeller [9] . Constructed 3D-model of blaOXA-1 was used for refinement and model quality validation. Energy minimization and refinement of predicted 3D model of blaOXA-1 was performed in swiss PDB viewer [10] . The refinement of the final model was carried out through energy minimization using 1000 iterations of steepest descent (SD) calculation to remove bad contacts between protein atoms. PROCHECK [11] was used for model quality evaluation.
After elucidation of final 3D model, the possible binding site of blaOXA-1 was searched using Q-siteFinder [12] . Q-siteFinder recognized ten binding sites for blaOXA-1 using van der Waal's probes and interaction energy. A set of 13 drugs were used for this docking study. [13] . Lamarckian genetic algorithm [14] was used to generate possible protein-ligand binding conformations.
Molecular dynamics and simulation for docked complexes (high and low affinity alone) were performed using the Gromacs 4.5.5 software [15] . The ligand parameters were analysed using PRODRG server [16] in the framework of the GROMOS force field 43a1 [17, 18] .
Results
Overall, 151 isolates were analysed by Kirby Bauer disk diffusion method and resistance to ampicillin (98.6%), cefotaxime (84.7%), cefpirome (81.4%), ceftazidime (79.4%), cefepime (70.8%), levofloxacin (61.5%), amikacin (61.5%), cefoxitin (44.3%), piperacillin/tazobactam (39%), ertapenem (24.5%), meropenem (23.8%), imipenem (22.5%), and tigecycline (15.7%) noted (Table 1 ). In our present study of 151 K. pneumoniae strains, 39% (59) are found to be resistant to piperacillin/tazobactam (blactam/inhibitor complex). These strains were selected for further testing to determine the MIC by E-test and results compared with disk diffusion method ( Figure 1 ). Among the 151 study isolates 122 (81%) were ESBL's and additionally 38 were carbapenem resistant. The Pearson correlation analysis showed there was a positive association between ESBL production and resistance to ampicillin, imipenem, ertapenem at p values of 0.003, 0.006 and 0.001 respectively, rest of the antibiotics had p values,0.001. Only in the case of tigecycline no statistically significant association (p value = 0.140) was observed between resistance and ESBL production.
MIC was performed for 59 K. pneumoniae inhibitor resistant isolates, and they were found to be resistant to ampicillin (100%), ceftazidime (100%), and cefotaxime (100%), piperacillin/tazobactam (100%), cefepime (93.2%), cefpirome (93.2%), levofloxacin (93.2%), amikacin (84.7%), cefoxitin (76.2%), ertapenem (61%), imipenem (54.2%) and meropenem (50.8%), all were susceptible to tigecycline (Figure 1 
Bioinfomatics
Homology modeling. The absence of the 3D-structure for blaOXA-1 from K. pneumoniae in PDB prompted us to construct the 3D-model of the protein of interest. The modelled strain was found to be suitable for in-silico analysis based on validation by Ramachandran Plot [11] . (Figure 3) Active site prediction and Docking. The active site renders on the modelled protein was identified using Q-siteFinder. Among the ten sites obtained from Q-siteFinder, site 2 is conserved in blaOXA-1 and therefore chosen as binding site for docking study. The active site amino acids strings are ILE15, ALA16, ILE19, ALA49, SER50, THR51, ASN52, PHE142, ASP143, TYR144, GLY145, GLU174, GLN177, PHE178, ARG180, LYS181, ASN184, ASN186 and LEU187. From the description of QsiteFinder it was observed that there was at least one successful prediction among the top three predicted site. The active residues are shown in surface model and represented in Figure 3 . Docking of modelled blaOXA-1 protein was done with b-lactam antibiotics Binding mode of Ceftazidime and Tigecycline in to model protein blaOXA-1. Binding mode of ceftazidime and tigecycline in model protein blaOXA-1 was analyzed. Ceftazidime resulted in the formation of 9 hydrogen bonds with the bond distance range of 1.9-3.3 Au and it was observed that side chain hydrogen atom of Lys181, Asn52, Ser21, Ile19 and Ile18 acts as hydrogen bond donor to interact with oxygen atom of the drug (Table 3 ). The best possible binding mode of ceftazidime in the blaOXA-1 binding site and corresponding 2D interaction models, hydrogen bonds and bond distance are shown in Figure 4 . Docking simulation of tigecycline into model protein blaOXA-1 of K. pneumoniae reveals weak binding as indicated by formation of fewer hydrogen bonds (3). The binding energy estimated by autodock was 21.99 Kcal/Mol, which is higher binding energy value when compare to standard drug ceftazidime. It indicates tigecycline has lower binding affinity with modeled protein blaOXA-1 ( Table 2, 3) . From the interaction residues analysis it is observed that only three residues Lys181, Ile19 and Asn52 contributed H-bond interaction with blaOXA-1 ( Figure 5 ). The comparative table with MIC results and binding energies are provided in Table 4 . MD simulation. MD simulations were carried out to explore the structural stabilities and protein internal motions within nanosecond (ns) time scale for ceftazidime-blaOXA-1 and tigecycline-blaOXA-1 complexes. The ceftazidime-blaOXA-1 and tigecycline-blaOXA-1 complexes were selected because ceftazidime has maximum binding energy (26.34 Kcal/Mol) and tigecycline has least binding energy (21.99 Kcal/Mol) with blaOXA-1. Each system was subjected to 5 ns MD simulations, and the results were analyzed to explore the stabilities and conformational changes of each complex. The root-mean-squaredeviation (RMSD), a crucial parameter to analyse the equilibration of MD trajectories, were estimated by using the ceftazidimeblaOXA-1 and tigecycline-blaOXA-1 complex. Figure 6 shows the RMSD of ceftazidime relative to blaOXA-1. This system approaches equilibrium at 5 ns and was stable throughout the MD simulation, indicating a stable binding of ceftazidime with blaOXA-1. Figure 7 shows that the RMSD of tigecycline-blaOXA-1 complex which increases within the first 2 ns, the complex was unstable throughout the simulation. Interaction between tigecycline and blaOXA-1 is weak throughout the simulation. The comparison of RMSD value of ceftazidime-blaOXA-1 and tigecycline blaOXA-1 complexes are shown in Figure 8 . RMSD values of tigecycline blaOXA-1 complex shows slight deviation when compared RMSD value of ceftazidime-blaOXA-1complex. The deviations described above indicate that how far the protein has moved from the native structure. It clearly indicates the interactions between tigecycline and blaOXA-1 is unstable throughout the simulation. 
Discussion
From our surveillance studies over the last 5 years, among 2782 Enterobacteriaceae strains, 285 isolates were carbapenem resistant. On analyzing a subset of these isolates (n = 86), a majority of them were found to carry ESBLs, Amp C and NDM enzymes mediating resistance. A few isolates were carbapenem resistant but negative for NDM, KPC, IMP and VIM, we therefore hypothesize that these isolates carry OXA mediated carbapenamase types and wished to explore this further (Manoharan A 2013-unpublished data). We believe OXA-1 co carriage along with ESBLs results in high levels of multidrug resistance including carbapenem resistance and proceeded to study this further. Further, given the high proportion of ESBLs which are screened and confirmed by the CLSI approved method of using clavulanic acid as an inhibitor we wished to evaluate tazobactam as an marker since this has been shown to possess a higher degree of [19] inhibitory activity against ESBLs as compared to clavulanic acid. Therefore we hypothesized that strains resistant to b-lactam plus clavulanic acid and b-lactam plus tazobactam would show high levels of multidrug resistance and proceeded to screen them for OXA-1 mediated resistance.
The prevalence of blaOXA-1-mediated resistance in India is not known, due to the limited number of surveillance studies seeking clinical strains producing OXA-1 b-lactamases and the difficulty that clinical microbiology laboratories have in accurately detecting this resistance mechanism. The present study showed phenotypic frequency of blaOXA-1 among K.pneumoniae in Indian medical centers is 39%, with commonly reported genotype seen among 20.3% of them.
In a previous study, 17 of 18 isolates obtained in 1989 primarily from patients with a history of travel to the Middle East, Asia, and Africa reported to produce a b-lactamase with similar properties to blaOXA-1. Ampicillin resistance in 75% of the S. flexneri strains was associated with the presence of OXA-1 type b-lactamase. Taken together, these findings suggest the probable occurrence of host preference for OXA-type b -lactamase in S. flexneri [20] .
In a study conducted at Hong Kong and Shanghai the production of b-lactamase from 91 ampicillin-resistant Shigella flexneri strains, blaTEM-1-like and blaOXA-1 like enzymes were identified in 21 and 79% of the strains. All blaOXA-type isolates had a low level of resistance to ampicillin, with MIC values of 128 or 256 mg/ml. All blaOXA-type isolates were susceptible to cephalothin and mercury chloride but resistant to streptomycin, chloramphenicol, spectinomycin, and tetracycline. The MICs of ampicillin/sulbactam and amoxicillin/clavulanate for blaOXAtype isolates were in the resistant range. The results suggested that blaOXA-type isolates are not inhibited by b-lactam-b-lactamase inhibitor combinations [21] .
Our results indicate that blaOXA-1 carrying strains of K.pneumoniae exhibited 100% susceptibility to tigecycline, 83.4% to imipenem, meropenem, and 75% to ertapenem. b-lactam and b-lactamase inhibitor resistance alongwith multi drug resistance was noted to be high among septicemic patients. Carbapenem resistance was found to be between 20 to 25% and it may be primarily due to the production of New Delhi Metallo-b-lactamase (NDM). Resistance to b-lactam and b-lactamase inhibitor is mediated through co-carriage of multiple enzymes necessitating alternative therapeutic approach. In a study in Spain conducted on 51 amoxicillin-clavulanic acidresistant strains tested by multiplex PCR, 45 isolates had blaTEM and only two have blaSHV genes. Only one isolate had a blaOXA-1 gene. The simultaneous presence of two b-lactamase genes was not detected in this population of E.coli isolates. Hyperproduction of cephalosporinase can be suspected in routine testing by the classical antibiogram but other methods must be used to differentiate the mechanisms involving plasmid-encoded amoxicillin-clavulanic acid. TEM and blaOXA-1 enzymes are the major plasmid borne b-lactamases implicated in amoxicillin-clavulanic acid resistance in E.coli [22] .
In our present findings majority of blaOXA-1 producing strains were resistant to b-lactamase inhibitor (piperacillin/tazobactam) but all are susceptible to tigecycline. Conventional PCR and insilco approaches are suitable tools for screening plasmid-mediated b-lactamases among K. pneumoniae strains. The 3D-structure provides valuable insight into molecular function and also enables the analyses of its interactions with suitable inhibitors. PRO-CHECK and ProSA results reveal that the quality of the blaOXA-1 model is good. On the basis of experimental data, molecular docking studies on b-lactam antibiotics reveal that ceftazidime has highest binding affinity with blaOXA-1 and tigecycline has least binding affinity with blaOXA-1. On comparing the number of hydrogen bonds, tigecycline formed less number of hydrogen bonds (3) with blaOXA-1. Further molecular docking results of ceftazidime and tigecycline was validated by molecular dynamics study and revealed that tigecycline-blaOXA-1 complex is unstable and hence the blaOXA-1 b-lactam may not be able to cleave tigecycline. From the molecular docking and molecular dynamics analysis, it is confirmed that blaOXA-1 showed strong binding affinity with ceftazidime, resulting in cleavage of the antibiotic which suggests the high efficiency of blaOXA-1 in cleaving the blactam antibiotics. On the other hand, the lowest binding affinity of tigecycline to blaOXA-1 clearly shows the low enzyme activity of blaOXA-1, which in turn correlates well with the fact that tigecycline, is a very potent antibiotic. binding affinity and thus bind strongly to b-lactam antibiotics resulting in cleavage of the antibiotic. Our insilico results are comparable to the in-vitro MIC values and disc diffusion which are presented in Table 1 and 4. At the study institution, the initial empiric treatment for severe, life threatening infections (associated with multi-organ dysfunction, septic shock) caused by Gramnegative bacteria is either imipenem or meropenem.Once the culture and susceptibility reports are available, the most appropriate antibiotic based on spectrum of activity, toxicity and cost ('de-escalation') is chosen. The result of the present study reenforce this approach. The present study documents the emergence of multidrug resistant strains with OXA-1 co carriage. Antibiotic therapy needs to be based on laboratory confirmation of susceptibility which will help prevent occurrence and spread of antibiotic resistant strains. 
